Nature Communications (Sep 2019)
The transcribed pseudogene RPSAP52 enhances the oncofetal HMGA2-IGF2BP2-RAS axis through LIN28B-dependent and independent let-7 inhibition
- Cristina Oliveira-Mateos,
- Anaís Sánchez-Castillo,
- Marta Soler,
- Aida Obiols-Guardia,
- David Piñeyro,
- Raquel Boque-Sastre,
- Maria E. Calleja-Cervantes,
- Manuel Castro de Moura,
- Anna Martínez-Cardús,
- Teresa Rubio,
- Joffrey Pelletier,
- Maria Martínez-Iniesta,
- David Herrero-Martín,
- Oscar M. Tirado,
- Antonio Gentilella,
- Alberto Villanueva,
- Manel Esteller,
- Lourdes Farré,
- Sonia Guil
Affiliations
- Cristina Oliveira-Mateos
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- Anaís Sánchez-Castillo
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- Marta Soler
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- Aida Obiols-Guardia
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- David Piñeyro
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- Raquel Boque-Sastre
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- Maria E. Calleja-Cervantes
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- Manuel Castro de Moura
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- Anna Martínez-Cardús
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- Teresa Rubio
- Laboratory of Cancer Metabolism, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- Joffrey Pelletier
- Laboratory of Cancer Metabolism, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- Maria Martínez-Iniesta
- Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, L’Hospitalet de Llobregat
- David Herrero-Martín
- Sarcoma Research Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- Oscar M. Tirado
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Carlos III Institute of Health (ISCIII)
- Antonio Gentilella
- Laboratory of Cancer Metabolism, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- Alberto Villanueva
- Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, L’Hospitalet de Llobregat
- Manel Esteller
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- Lourdes Farré
- Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, L’Hospitalet de Llobregat
- Sonia Guil
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat
- DOI
- https://doi.org/10.1038/s41467-019-11910-6
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 18
Abstract
RPSAP52 is an antisense-transcribed pseudogene of HMGA2 that positively regulates HMGA2 expression. Here, the authors show that reexpression of RPSAP52 promotes tumorigenicity by facilitating IGF2BP2 binding to its mRNA targets and consequently regulates the balance of LIN28B and let-7 levels.
